Novavax
NVAX
252 hedge funds and large institutions have $540M invested in Novavax in 2022 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 79 increasing their positions, 64 reducing their positions, and 44 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 64
15.57% more ownership
Funds ownership: 46.34% → 61.91% (+16%)
5% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 44
2% more call options, than puts
Call options by funds: $124M | Put options by funds: $121M
0% less funds holding
Funds holding: 253 → 252 (-1)
18% less capital invested
Capital invested by funds: $657M → $540M (-$117M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$42.7M |
| 2 |
Renaissance Technologies
New York
|
+$34.3M |
| 3 |
VA
VR Adviser
New York
|
+$33.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$23.8M |
| 5 |
Millennium Management
New York
|
+$18.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$11.8M |
| 2 |
Voloridge Investment Management
Jupiter,
Florida
|
-$10.3M |
| 3 |
N
Natixis
Paris,
France
|
-$7.86M |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
-$4.56M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$4.54M |
NVAX Hedge Fund Activity: Q4 2022 in Review
252 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q4 2022, worth a combined $540M — down 18% from $657M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new NVAX positions and 44 closed out — a net gain of 2 holders — while 79 added to existing stakes and 64 trimmed.
The largest buyer was State Street, adding an estimated $42.7M. The largest seller was Citadel Advisors, cutting an estimated $11.8M.
- 252 institutional investors held Novavax (NVAX) as of Q4 2022, down from 253 in Q3 2022.
- Funds reported $540M of Novavax stock for Q4 2022, down 18% quarter-over-quarter.
- 46 funds opened new Novavax positions in Q4 2022 and 44 closed out, a net change of +2 holders.
- The largest Novavax buyer in Q4 2022 was State Street, an estimated $42.7M added.
- The largest Novavax seller in Q4 2022 was Citadel Advisors, an estimated $11.8M sold.
Based on aggregated 13F filings for Q4 2022.